Navigation Links
FDA Warns Drug Makers to Stop Selling Unapproved Prescription Painkillers
Date:3/31/2009

Action should not affect consumers or lead to shortages, the agency says,,,,

TUESDAY, March 31 (HealthDay News) -- The U.S. Food and Drug Administration on Tuesday warned nine companies to stop making 14 unapproved prescription narcotic painkillers.

These unapproved products pose a risk for consumers, Deborah Autor, director of the Office of Compliance at the FDA's Center for Drug Evaluation and Research, said during a morning teleconference. "These include respiratory depression and other serious adverse events, including death," she said.

The action is part of an ongoing effort to remove unapproved medicines from the market; roughly 2 percent of all prescriptions in the United States are filled with unapproved drugs, the FDA said.

This latest batch of warning letters tells the companies they could face enforcement action if they do not stop making and selling these unapproved drugs, including high concentrate morphine sulfate oral solutions and immediate release tablets containing morphine sulfate, hydromorphone or oxycodone. Oxycodone capsules and approved tablets are not included in this warning, the agency noted.

"The FDA wants to assure consumers who rely on these products for pain relief that they will still have access to FDA-approved narcotic drugs and there will be no shortage for consumers," Autor said.

The companies have 60 days to stop manufacturing these products and 90 days to stop distributing them, Autor said. "FDA expects all manufacturers and distributors of unapproved versions of these products to honor these deadlines and will not tolerate any manufacture or distribution after these deadlines," she added.

The companies getting warning letters are: Boehringer Ingelheim Roxane Inc., of Columbus, Ohio; Cody Laboratories Inc., Cody, Wyo.; Glenmark Pharmaceuticals Inc., Mahwah, N.J.; Lannett Co., Philadelphia; Lehigh Valley Technologies Inc., Allentown, Pa.; Mallinckrodt Inc. Pharmaceuticals Group, St. Louis; Physicians Total Care Inc., Tulsa, Okla.; Roxane Laboratories Inc., Columbus, Ohio; and Xanodyne Pharmaceuticals Inc., Newport, Ky.

The market share of these unapproved pain products varies from product to product. One product slated to be removed from the market has about a 4 percent market share, while another unapproved product represents about 53 percent of the market, Autor said.

"Today's action is about ensuring that Americans have safe and effective drugs and getting the message to companies that they have a responsibility to patients that they should actively pursue FDA approval for their illegally marketed products," Autor said.

The FDA's pursuit of unapproved drugs began in 2006, and to date the agency's action has taken more than 500 unapproved drugs off the market from over 200 drug companies, Autor said. There are still several thousand unapproved drugs on the market, she added.

More information

For more on unapproved drugs, visit the U.S. Food and Drug Administration.



SOURCES: March 31, 2009, teleconference with Deborah Autor, J.D., director, Office of Compliance, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Md.


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Warns of Codeine Risk for Some Nursing Mothers
2. PA Agriculture Department Warns Consumers of Tainted Raw Milk Sold by Perry County Dairy
3. Research warns that human papillomavirus might cause bladder cancer
4. New research warns of the lack of specialization when judging individuals with mental disorders
5. Coalition of Caregivers Warns Congress of Danger to Oldest U.S. Seniors if Medicare Slashed
6. Health Department Warns Consumers of Home-Canned Soup Linked to Potter County Restaurant
7. FDA Warns Against Bio-Identical Hormone Therapy
8. Cold Meds Not Safe for Kids Under 2, FDA Warns
9. FDA Warns Clot Risk Higher in Birth Control Patch Than Pill
10. Renaissance Health Publishing, LLC Warns the Public that ConsumerLab.com is Not Independent and Labels the CL Seal of Approval a Worthless, Paid-For Advertising Gimmick
11. Health Capital Group Warns of Fallout to Hospitals From the Subprime Mortgage Crisis and Urges Hospitals to Immediately Reassess Existing Debt Structures and Capital Financing Plans
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Warns Drug Makers to Stop Selling Unapproved Prescription Painkillers
(Date:10/13/2017)... ... October 13, 2017 , ... ... in the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity ... a rare and deadly chromosome abnormality. , After struggling since birth with several ...
(Date:10/13/2017)... ... 13, 2017 , ... The International Association of Eating Disorders ... for the field of eating disorders, announces the opening of early registration for ... Florida at the Omni Resort at ChampionsGate. , The annual iaedp™ ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
Breaking Medicine Technology: